Boston Scientific Co. (NYSE:BSX) Shares Sold by Picton Mahoney Asset Management

Picton Mahoney Asset Management cut its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 1.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 281,121 shares of the medical equipment provider's stock after selling 2,858 shares during the period. Boston Scientific makes up 0.7% of Picton Mahoney Asset Management's holdings, making the stock its 24th largest position. Picton Mahoney Asset Management's holdings in Boston Scientific were worth $25,112,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in Boston Scientific during the 4th quarter worth about $190,780,000. State Street Corp grew its holdings in Boston Scientific by 2.3% during the third quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock worth $5,266,522,000 after acquiring an additional 1,389,172 shares during the period. Fisher Funds Management LTD purchased a new position in Boston Scientific during the fourth quarter valued at approximately $94,710,000. Fisher Asset Management LLC lifted its holdings in Boston Scientific by 21.6% in the fourth quarter. Fisher Asset Management LLC now owns 5,800,912 shares of the medical equipment provider's stock valued at $518,138,000 after acquiring an additional 1,028,977 shares during the period. Finally, Impax Asset Management Group plc boosted its position in Boston Scientific by 17.5% in the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider's stock worth $457,138,000 after purchasing an additional 815,403 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Boston Scientific Trading Up 0.2 %

Boston Scientific stock traded up $0.17 during trading on Tuesday, reaching $99.07. 2,043,917 shares of the company were exchanged, compared to its average volume of 5,729,808. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The stock's 50 day simple moving average is $101.21 and its two-hundred day simple moving average is $91.97. The company has a market capitalization of $146.21 billion, a P/E ratio of 79.22, a PEG ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 52-week low of $66.16 and a 52-week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. On average, equities research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the firm's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now owns 35,319 shares of the company's stock, valued at $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 137,302 shares of company stock valued at $14,319,269. 0.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

BSX has been the subject of several recent research reports. Wells Fargo & Company lifted their target price on shares of Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a research note on Monday, March 3rd. StockNews.com downgraded Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. UBS Group boosted their price objective on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. increased their target price on Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $108.91.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.